Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 57, 4183-4186, October 1, 1997]
© 1997 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, S. I.
Right arrow Articles by Parsons, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, S. I.
Right arrow Articles by Parsons, R.

Somatic Mutations of PTEN in Glioblastoma Multiforme

Steven I. Wang, Janusz Puc, Jing Li, Jeffrey N. Bruce, Paul Cairns, David Sidransky and Ramon Parsons1

Departments of Pathology and Medicine [S. I. W., J. P., J. L., R. P.] and Neurological Surgery [J. N. B.], College of Physicians and Surgeons, Columbia University, West 168th Street, New York, New York 10032, and Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196 [P. C., D. S.]

Alterations of the PTEN gene occur in glioblastoma multiforme. To determine the frequency of PTEN alteration, 34 consecutive glioblastomas were studied in detail. Sequencing each of the nine exons amplified from tumor DNA revealed 11 mutations. Analysis of polymorphic markers within and surrounding the PTEN gene identified an additional four homozygous deletion mutations. Loss of heterozygosity (LOH) was observed in 25 of 34 (74%) cases. All mutations occurred in the presence of LOH. PTEN was mutated in 44% (15 of 34) of all glioblastomas studied and 60% (15 of 25) of tumors with LOH on 10q. Thus, PTEN appears to be the major target of inactivation on chromosome 10q in glioblastoma multiforme.

1 To whom requests for reprints should be addressed, at Department of Pathology and Medicine, Columbia University, 630 West 168th Street, New York, NY 10032. Phone: (212) 305-1058; Fax: (212) 305-1735.

Received 7/21/97. Accepted 8/15/97.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. H. Lu, W. Wu, B. Dave, B. M. Slomovitz, T. W. Burke, M. F. Munsell, R. R. Broaddus, and C. L. Walker
Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma
Clin. Cancer Res., May 1, 2008; 14(9): 2543 - 2550.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Takei, Y. Saga, H. Mizukami, T. Takayama, M. Ohwada, K. Ozawa, and M. Suzuki
Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice
Mol. Cancer Ther., March 1, 2008; 7(3): 704 - 711.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. M. Emerling, F. Weinberg, J.-L. Liu, T. W. Mak, and N. S. Chandel
PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a)
PNAS, February 19, 2008; 105(7): 2622 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. A. Edwards, J. Woo, L. A. Huxham, M. Verreault, W. H. Dragowska, G. Chiu, A. Rajput, A. H. Kyle, J. Kalra, D. Yapp, et al.
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK)
Mol. Cancer Ther., January 1, 2008; 7(1): 59 - 70.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. M. Dunlap, J. Celestino, H. Wang, R. Jiang, E. C. Holland, G. N. Fuller, and W. Zhang
Insulin-like growth factor binding protein 2 promotes glioma development and progression
PNAS, July 10, 2007; 104(28): 11736 - 11741.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Jiang, N. Pore, G. J. Cerniglia, R. Mick, M.-M. Georgescu, E. J. Bernhard, S. M. Hahn, A. K. Gupta, and A. Maity
Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir
Cancer Res., May 1, 2007; 67(9): 4467 - 4473.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
D. A. Altman, D. S. Atkinson Jr, and D. J. Brat
Best Cases from the AFIP: Glioblastoma Multiforme
RadioGraphics, May 1, 2007; 27(3): 883 - 888.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Kotliarov, M. E. Steed, N. Christopher, J. Walling, Q. Su, A. Center, J. Heiss, M. Rosenblum, T. Mikkelsen, J. C. Zenklusen, et al.
High-resolution Global Genomic Survey of 178 Gliomas Reveals Novel Regions of Copy Number Alteration and Allelic Imbalances
Cancer Res., October 1, 2006; 66(19): 9428 - 9436.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer.
Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
J. PUC, G. PLACHA, B. WOCIAL, K. PODSYPANINA, R. PARSONS, and Z. GACIONG
Analysis of PTEN Mutation in Non-familial Pheochromocytoma.
Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 317 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
J. V. Schaffer, H. Kamino, A. Witkiewicz, J. M. McNiff, and S. J. Orlow
Mucocutaneous Neuromas: An Underrecognized Manifestation of PTEN Hamartoma-Tumor Syndrome.
Arch Dermatol, May 1, 2006; 142(5): 625 - 632.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
J. Clin. Oncol., August 10, 2005; 23(23): 5294 - 5304.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Shin, J. Edl, S. Biswas, P. C. Lin, R. Mernaugh, and C. L. Arteaga
Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies
Cancer Res., April 1, 2005; 65(7): 2815 - 2824.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Kang, A. G. Bader, and P. K. Vogt
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
PNAS, January 18, 2005; 102(3): 802 - 807.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Sansal and W. R. Sellers
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
J. Clin. Oncol., July 15, 2004; 22(14): 2954 - 2963.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Stahl, M. Cheung, A. Sharma, N. R. Trivedi, S. Shanmugam, and G. P. Robertson
Loss of PTEN Promotes Tumor Development in Malignant Melanoma
Cancer Res., June 1, 2003; 63(11): 2881 - 2890.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
S. Marino, P. Krimpenfort, C. Leung, H. A. G. M. van der Korput, J. Trapman, I. Camenisch, A. Berns, and S. Brandner
PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum
Development, March 9, 2003; 129(14): 3513 - 3522.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Narita, M. Nagane, K. Mishima, H-J. S. Huang, F. B. Furnari, and W. K. Cavenee
Mutant Epidermal Growth Factor Receptor Signaling Down-Regulates p27 through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Glioblastomas
Cancer Res., November 15, 2002; 62(22): 6764 - 6769.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
L.-P. Weng, J. L. Brown, K. M. Baker, M. C. Ostrowski, and C. Eng
PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway
Hum. Mol. Genet., July 15, 2002; 11(15): 1687 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
C. B. Knobbe, A. Merlo, and G. Reifenberger
Pten signaling in gliomas
Neuro-oncol, July 1, 2002; 4(3): 196 - 211.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
R. P. Ermoian, C. S. Furniss, K. R. Lamborn, D. Basila, M. S. Berger, A. R. Gottschalk, M. K. Nicholas, D. Stokoe, and D. A. Haas-Kogan
Dysregulation of PTEN and Protein Kinase B Is Associated with Glioma Histology and Patient Survival
Clin. Cancer Res., May 1, 2002; 8(5): 1100 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Powers, A. Aigner, G. E. Stoica, K. McDonnell, and A. Wellstein
Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth
J. Biol. Chem., April 12, 2002; 277(16): 14153 - 14158.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Li, D. Dowbenko, and L. A. Lasky
AKT/PKB Phosphorylation of p21Cip/WAF1 Enhances Protein Stability of p21Cip/WAF1 and Promotes Cell Survival
J. Biol. Chem., March 22, 2002; 277(13): 11352 - 11361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dicuonzo, S. Angeletti, J. Garcia-Foncillas, A. Brugarolas, Y. Okrouzhnov, D. Santini, G. Tonini, G. Lorino, M. De Cesaris, and A. Baldi
Colorectal Carcinomas and PTEN/MMAC1 Gene Mutations
Clin. Cancer Res., December 1, 2001; 7(12): 4049 - 4053.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Chakravarti, M. A. Delaney, E. Noll, P. McL. Black, J. S. Loeffler, A. Muzikansky, and N. J. Dyson
Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas
Clin. Cancer Res., August 1, 2001; 7(8): 2387 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Sasaki, M. C. Zlatescu, R. A. Betensky, Y. Ino, J. G. Cairncross, and D. N. Louis
PTEN Is a Target of Chromosome 10q Loss in Anaplastic Oligodendrogliomas and PTEN Alterations Are Associated with Poor Prognosis
Am. J. Pathol., July 1, 2001; 159(1): 359 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zhu, C.-H. Kwon, P. W. Schlosshauer, L. H. Ellenson, and S. J. Baker
PTEN Induces G1 Cell Cycle Arrest and Decreases Cyclin D3 Levels in Endometrial Carcinoma Cells
Cancer Res., June 1, 2001; 61(11): 4569 - 4575.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
E. A. Maher, F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. Cavenee, and R. A. DePinho
Malignant glioma: genetics and biology of a grave matter
Genes & Dev., June 1, 2001; 15(11): 1311 - 1333.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. L. Mutter
PTEN, a Protean Tumor Suppressor
Am. J. Pathol., June 1, 2001; 158(6): 1895 - 1898.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
L.-P. Weng, O. Gimm, J. B. Kum, W. M. Smith, X.-P. Zhou, D. Wynford-Thomas, G. Leone, and C. Eng
Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death
Hum. Mol. Genet., February 1, 2001; 10(3): 251 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
N. Nakamura, S. Ramaswamy, F. Vazquez, S. Signoretti, M. Loda, and W. R. Sellers
Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN
Mol. Cell. Biol., December 1, 2000; 20(23): 8969 - 8982.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
X.-P. Zhou, O. Gimm, H. Hampel, T. Niemann, M. J. Walker, and C. Eng
Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation
Am. J. Pathol., October 1, 2000; 157(4): 1123 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kato, S. Kato, T. Kumabe, Y. Sonoda, T. Yoshimoto, S. Kato, S.-Y. Han, T. Suzuki, H. Shibata, R. Kanamaru, et al.
Functional Evaluation of p53 and PTEN Gene Mutations in Gliomas
Clin. Cancer Res., October 1, 2000; 6(10): 3937 - 3943.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
A. H. Holway, K. M. Rieger-Christ, W. R. Miner, J. W. Cain, J. M. Dugan, J. A. Pezza, M. L. Silverman, A. Shapter, R. McLellan, and I. C. Summerhayes
Somatic Mutation of PTEN in Vulvar Cancer
Clin. Cancer Res., August 1, 2000; 6(8): 3228 - 3235.
[Abstract] [Full Text]

Home page
 Neuro OncolHome page
R. N. Wiltshire, B.K. A. Rasheed, H. S. Friedman, A. H. Friedman, and S. H. Bigner
Comparative genetic patterns of glioblastoma multiforme: Potential diagnostic tool for tumor classification
Neuro-oncol, July 1, 2000; 2(3): 164 - 173.
[Abstract] [PDF]

Home page
 Hum Mol GenetHome page
O. Gimm, T. Attie-Bitach, J. A. Lees, M. Vekemans, and C. Eng
Expression of the PTEN tumour suppressor protein during human development
Hum. Mol. Genet., July 1, 2000; 9(11): 1633 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Stambolic, M.-S. Tsao, D. Macpherson, A. Suzuki, W. B. Chapman, and T. W. Mak
High Incidence of Breast and Endometrial Neoplasia Resembling Human Cowden Syndrome in pten+/- Mice
Cancer Res., July 1, 2000; 60(13): 3605 - 3611.
[Abstract] [Full Text]

Home page
 Neuro OncolHome page
D. Fults and C. Pedone
Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas
Neuro-oncol, April 1, 2000; 2(2): 71 - 79.
[Abstract] [PDF]

Home page
 J. Med. Genet.Home page
M. S FORREST, S. M EDWARDS, R. A HAMOUDI, D. P DEARNALEY, A. ARDEN-JONES, A. DOWE, A. MURKIN, J. KELLY, M D. TEARE, D. F EASTON, et al.
No evidence of germline PTEN mutations in familial prostate cancer
J. Med. Genet., March 1, 2000; 37(3): 210 - 212.
[Full Text]

Home page
 Toxicol PatholHome page
P. Kleihues and H. Ohgaki
Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors
Toxicol Pathol, January 1, 2000; 28(1): 164 - 170.
[Abstract] [PDF]

Home page
 Genes Dev.Home page
D. C.I. Goberdhan, N. Paricio, E. C. Goodman, M. Mlodzik, and C. Wilson
Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway
Genes & Dev., December 15, 1999; 13(24): 3244 - 3258.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
I. U. Ali, L. M. Schriml, and M. Dean
Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity
J Natl Cancer Inst, November 17, 1999; 91(22): 1922 - 1932.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Perren, L.-P. Weng, A. H. Boag, U. Ziebold, K. Thakore, P. L. M. Dahia, P. Komminoth, J. A. Lees, L. M. Mulligan, G. L. Mutter, et al.
Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast
Am. J. Pathol., October 1, 1999; 155(4): 1253 - 1260.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W. R. Sellers
Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer Correlates with High Gleason Score and Advanced Stage
Cancer Res., September 1, 1999; 59(17): 4291 - 4296.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hahn, I. Wieland, O. N. Koufaki, H. Gorgens, S. B. Sobottka, G. Schackert, and H. K. Schackert
Genetic Alterations of the Tumor Suppressor Gene PTEN/MMAC1 in Human Brain Metastases
Clin. Cancer Res., September 1, 1999; 5(9): 2431 - 2437.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M.-M. Georgescu, K. H. Kirsch, T. Akagi, T. Shishido, and H. Hanafusa
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region
PNAS, August 31, 1999; 96(18): 10182 - 10187.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Fujisawa, M. Kurrer, R. M. Reis, Y. Yonekawa, P. Kleihues, and H. Ohgaki
Acquisition of the Glioblastoma Phenotype during Astrocytoma Progression Is Associated with Loss of Heterozygosity on 10q25-qter
Am. J. Pathol., August 1, 1999; 155(2): 387 - 394.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Ebert, M. von Haken, B. Meyer-Puttlitz, O. D. Wiestler, G. Reifenberger, T. Pietsch, and A. von Deimling
Molecular Genetic Analysis of Ependymal Tumors : NF2 Mutations and Chromosome 22q Loss Occur Preferentially inIntramedullary Spinal Ependymomas
Am. J. Pathol., August 1, 1999; 155(2): 627 - 632.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tamura, J. Gu, E. H. J. Danen, T. Takino, S. Miyamoto, and K. M. Yamada
PTEN Interactions with Focal Adhesion Kinase and Suppression of the Extracellular Matrix-dependent Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway
J. Biol. Chem., July 16, 1999; 274(29): 20693 - 20703.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Cooney, H. C. Tsou, E. M. Petty, S. Miesfeldt, X. L. Ping, A. C. Gruener, and M. Peacocke
Absence of PTEN Germ-Line Mutations in Men with a Potential Inherited Predisposition to Prostate Cancer
Clin. Cancer Res., June 1, 1999; 5(6): 1387 - 1391.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. C. Cantley and B. G. Neel
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
PNAS, April 13, 1999; 96(8): 4240 - 4245.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression
Neuro-oncol, April 1, 1999; 1(2): 124 - 137.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Podsypanina, L. H. Ellenson, A. Nemes, J. Gu, M. Tamura, K. M. Yamada, C. Cordon-Cardo, G. Catoretti, P. E. Fisher, and R. Parsons
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
PNAS, February 16, 1999; 96(4): 1563 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
H Huang, C. Potter, W Tao, D. Li, W Brogiolo, E Hafen, H Sun, and T Xu
PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development
Development, January 12, 1999; 126(23): 5365 - 5372.
[Abstract] [PDF]

Home page
 Neuro OncolHome page
P. Kleihues and H. Ohgaki
Primary and secondary glioblastomas: From concept to clinical diagnosis
Neuro-oncol, January 1, 1999; 1(1): 44 - 51.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
M. Tamura, J. Gu, T. Takino, and K. M. Yamada
Tumor Suppressor PTEN Inhibition of Cell Invasion, Migration, and Growth: Differential Involvement of Focal Adhesion Kinase and p130Cas
Cancer Res., January 1, 1999; 59(2): 442 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. P. Myers, I. Pass, I. H. Batty, J. Van der Kaay, J. P. Stolarov, B. A. Hemmings, M. H. Wigler, C. P. Downes, and N. K. Tonks
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
PNAS, November 10, 1998; 95(23): 13513 - 13518.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Sakai, C. Thieblemont, A. Wellmann, E. S. Jaffe, and M. Raffeld
PTEN Gene Alterations in Lymphoid Neoplasms
Blood, November 1, 1998; 92(9): 3410 - 3415.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Z.-J. Wang, F. Taylor, M. Churchman, G. Norbury, and I. Tomlinson
Genetic Pathways of Colorectal Carcinogenesis Rarely Involve the PTEN and LKB1 Genes Outside the Inherited Hamartoma Syndromes
Am. J. Pathol., August 1, 1998; 153(2): 363 - 366.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics